ES2145694B1 - Metodo de aislamiento de un agregado celular y agregado celular resultante. - Google Patents

Metodo de aislamiento de un agregado celular y agregado celular resultante.

Info

Publication number
ES2145694B1
ES2145694B1 ES009800313A ES9800313A ES2145694B1 ES 2145694 B1 ES2145694 B1 ES 2145694B1 ES 009800313 A ES009800313 A ES 009800313A ES 9800313 A ES9800313 A ES 9800313A ES 2145694 B1 ES2145694 B1 ES 2145694B1
Authority
ES
Spain
Prior art keywords
cells
cellular
added
tissue
aggregate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES009800313A
Other languages
English (en)
Other versions
ES2145694A1 (es
Inventor
Butron De Mugica Jose Armengol
Espejo Emilio Fernandez
Laseca Rafael Jesus Montoro
Barneo Jose Lopez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad de Sevilla
Original Assignee
Universidad de Sevilla
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad de Sevilla filed Critical Universidad de Sevilla
Priority to ES009800313A priority Critical patent/ES2145694B1/es
Priority to PCT/IB1999/000246 priority patent/WO1999040924A2/en
Publication of ES2145694A1 publication Critical patent/ES2145694A1/es
Application granted granted Critical
Publication of ES2145694B1 publication Critical patent/ES2145694B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Método de aislamiento de un agregado celular y agregado celular resultante.La invención se refiere al uso de células o agregados de células sensibles a hipoxia, por ejemplo del cuerpo carotídeo, sometidos o no a un tratamiento enzimático suave, que no llegue a disgregar el tejido en células aisladas. De este modo, el tejido se trata enzimáticamente pero no se dispersa mecánicamente. Las células segregan neurotransmisores, neuromoduladores o enzimas y podrían ser de utilidad para el tratamiento de enfermedades neurodegenerativas originadas por el déficit de una molécula, que sería el producto de secreción de las células trasplantadas. Es de destacar que las célulassegregan en respuesta a la hipoxia y, en un cerebro huésped, las células trasplantadas se van a encontrar en una situación de baja presión parcial de oxígeno, estimulante de la secreción.
ES009800313A 1998-02-11 1998-02-11 Metodo de aislamiento de un agregado celular y agregado celular resultante. Expired - Fee Related ES2145694B1 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES009800313A ES2145694B1 (es) 1998-02-11 1998-02-11 Metodo de aislamiento de un agregado celular y agregado celular resultante.
PCT/IB1999/000246 WO1999040924A2 (en) 1998-02-11 1999-02-11 Treatment of neurodegeneration

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009800313A ES2145694B1 (es) 1998-02-11 1998-02-11 Metodo de aislamiento de un agregado celular y agregado celular resultante.

Publications (2)

Publication Number Publication Date
ES2145694A1 ES2145694A1 (es) 2000-07-01
ES2145694B1 true ES2145694B1 (es) 2001-02-01

Family

ID=8302792

Family Applications (1)

Application Number Title Priority Date Filing Date
ES009800313A Expired - Fee Related ES2145694B1 (es) 1998-02-11 1998-02-11 Metodo de aislamiento de un agregado celular y agregado celular resultante.

Country Status (2)

Country Link
ES (1) ES2145694B1 (es)
WO (1) WO1999040924A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2578165A1 (en) * 2011-10-08 2013-04-10 Martin Ivanov Denev Method for stopping aging of the body by replacing of the old biocathode centers by young biocathode centers

Also Published As

Publication number Publication date
ES2145694A1 (es) 2000-07-01
WO1999040924A3 (en) 1999-11-25
WO1999040924A2 (en) 1999-08-19

Similar Documents

Publication Publication Date Title
IL139826A0 (en) BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF IgE
Girish et al. Snake venom hyaluronidase: an evidence for isoforms and extracellular matrix degradation
WO2005055944A3 (en) Oligosaccharide compositions and use thereof in the treatment of infection
WO2002098210A3 (en) Chromosome doubling method
BR0207811A (pt) Compostos de uréia aril e heteroaril substituìdos úteis no tratamento de doenças
HK1097841A1 (en) Multicyclic compounds and their use as inhibitors of parp, vegfr2 and mlk3 enzymes
MXJL03000027A (es) Compuestos de benzimidazol para modular la ige e inhibir la proliferacion celular.
CA2391098A1 (en) Recombinant .alpha.-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
MX9803851A (es) Compuestos macrociclicos novedosos como inhibidores de metaloproteasas.
PH12020500607A1 (en) Method for improving quality of aquaculture pond water using a nutrient germinant composition and spore incubation method
AU2001276361A1 (en) Regulation of human transmembrane serine protease
WO2002089730A3 (en) Compounds and methods for the modulation of cd154
GB1537509A (en) Method of preparing a component consisting of sugar lipid and protein derived from pseudomonas aeruginosa which possesses anti-tumor and interferon-inducing properties
ATE332411T1 (de) Enzymatische pressfilzbehandlung
MX2023002675A (es) Métodos de purificación de proteína en ph alcalino.
WO2023288007A9 (en) Expansion of memory natural killer cells
ES2145694B1 (es) Metodo de aislamiento de un agregado celular y agregado celular resultante.
ATE471985T1 (de) Protease from lucilia sericata und deren verwendung zur wundheilung
EA199700241A1 (ru) Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран
ES2099714T3 (es) Procedimiento de tratamiento endoproteolitico de las proteinas (precursores) y de produccion microbiologica de proteinas.
MXPA02010724A (es) Composicion para reducir la irritacion enzimatica de la piel.
AU7385398A (en) Novel macrocyclic compounds as metalloprotease inhibitors
AR008189A1 (es) Proceso para tratar proteinas vegetales y productos alimenticios preparados a partir de las mismas
AUPQ647600A0 (en) Pharmaceutical gel composition
Bowman et al. Identification of ribonuclease P activity from chick embryos

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20000701

Kind code of ref document: A1

Effective date: 20000701

FD2A Announcement of lapse in spain

Effective date: 20180525